These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15977036)

  • 1. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
    Tilson L; Bennett K; Barry M
    Eur J Health Econ; 2005 Sep; 6(3):267-73. PubMed ID: 15977036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.
    Heinze G; Hronsky M; Reichardt B; Baumgärtel C; Müllner M; Bucsics A; Winkelmayer WC
    Appl Health Econ Health Policy; 2015 Apr; 13(2):193-205. PubMed ID: 25536928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Generic drug prescribing: pilot study on the impact of the new drug pricing system on costs and potential savings].
    Wasserfallen JB; Shimia S; Biollaz J; Pannatier A
    Rev Med Suisse; 2006 Mar; 2(59):865-6, 868-71. PubMed ID: 16646370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
    McGowan B; Bennett K; Tilson L; Barry M
    Ir Med J; 2005 Mar; 98(3):78-80. PubMed ID: 15869064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing and reimbursement of drugs in Ireland.
    Barry M; Tilson L; Ryan M
    Eur J Health Econ; 2004 Jun; 5(2):190-4. PubMed ID: 15452757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.
    Gumbs PD; Verschuren WM; Souverein PC; Mantel-Teeuwisse AK; de Wit GA; de Boer A; Klungel OH
    Br J Clin Pharmacol; 2007 Nov; 64(5):680-5. PubMed ID: 17875197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The implications of regional and national demographic projections for future GMS costs in Ireland through to 2026.
    Conway A; Kenneally M; Woods N; Thummel A; Ryan M
    BMC Health Serv Res; 2014 Oct; 14():477. PubMed ID: 25335968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community drug expenditure and recent cost containment measures.
    Walshe V; Kenneally M
    Ir Med J; 2013 Feb; 106(2):44-6. PubMed ID: 23472384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden.
    Andersson K; Sonesson C; Petzold M; Carlsten A; Lönnroth K
    Pharmacoepidemiol Drug Saf; 2005 May; 14(5):341-8. PubMed ID: 15624198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic utilisation on the general medical services scheme in 2001.
    Igoe G
    Ir Med J; 2003; 96(10):315. PubMed ID: 14870821
    [No Abstract]   [Full Text] [Related]  

  • 17. Ageing, health status and coverage rate effects on community prescription costs in Ireland.
    Kenneally M; Lynch B
    Eur J Health Econ; 2018 Jun; 19(5):687-695. PubMed ID: 28639034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(6):1637-47. PubMed ID: 17102189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of lipid lowering therapy in Ireland.
    Barry M; Heerey A; Sheehan O; Ryan M; McCulloch D; Feely J
    Ir Med J; 1999; 92(7):430-2. PubMed ID: 10967865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.